BeiGene Announces Oral Presentation and Posters at the 59th American Society of Hematology Annual Meeting

On November 1, 2017 BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, reported that it will present data on its Bruton’s Tyrosine Kinase (BTK) inhibitor at the upcoming 59th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting (Press release, BeiGene, NOV 1, 2017, View Source [SID1234521450]). ASH (Free ASH Whitepaper) will take place December 9-12, 2017 in Atlanta, GA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentation, Abstract #152

Title: Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin’s Lymphoma

Presenter: Constantine Tam, MD

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma – Clinical Studies: Mantle Cell Lymphoma, New Therapies
Date & Time: 12:15pm EST, Saturday, December 9, 2017
Location: Georgia World Congress Center, A411-A412

Poster, Abstract #1745

Title: BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma

Presenter: Constantine Tam, MD

Session: 642. CLL: Therapy, excluding Transplantation: Poster I
Date & Time: 5:30pm-7:30pm EST, Saturday, December 9, 2017
Location: Georgia World Congress Center, Hall A2

Poster, Abstract #4057

Title: Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies

Presenter: Gavin Cull, MD

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma – Clinical Studies: Poster III
Date & Time: 6:00pm-8:00pm EST, Monday, December 11, 2017
Location: Georgia World Congress Center, Hall A2

About BGB-3111

BGB-3111 is a potent and highly selective investigational small molecule inhibitor of BTK. BGB-3111 has demonstrated higher selectivity against BTK than ibrutinib, a BTK inhibitor currently approved by the U.S. Food and Drug Administration and the European Medicines Agency, based on biochemical assays, higher exposure than ibrutinib based on their respective Phase 1 experience in separate studies, and sustained 24-hour BTK occupancy in both the peripheral blood and lymph node compartments.

About BGB-A317

BGB-A317 is an investigational humanized monoclonal antibody that belongs to a class of immuno-oncology agents known as immune checkpoint inhibitors. It is designed to bind to PD-1, a cell surface receptor that plays an important role in downregulating the immune system by preventing the activation of T-cells. BGB-A317 has high affinity and specificity for PD-1. It is differentiated from the currently approved PD-1 antibodies in an engineered Fc region, which is believed to minimize potentially negative interactions with other immune cells. BGB-A317 is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. BeiGene and Celgene Corporation have a global strategic collaboration for BGB-A317 for solid tumors.

Alpine Immune Sciences to Present at Two Upcoming Investor Conferences in November

On November 1, 2017 Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune diseases and cancer, reported that the company will present at two upcoming investor conferences in November (Press release, Alpine Immune Sciences, NOV 1, 2017, View Source [SID1234521449]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stifel 2017 Healthcare Conference
Tuesday, November 14, 2017, at 3:30 p.m. Eastern Time in New York.

29th Annual Piper Jaffray Healthcare Conference
Wednesday, November 29, 2017, at 10:50 a.m. Eastern Time in New York.

A live webcast of each presentation will be available online by visiting the investor relations page of the Company’s website, at View Source An archive of each webcast will be available on the Company’s website for 30 days.

Kura Oncology Announces Upcoming Presentations at American Society of Hematology Annual Meeting

On November 1, 2017 Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, reported that four abstracts relating to the Company’s lead product candidate, tipifarnib, have been accepted for presentation at the upcoming American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, which will be held from December 9-12, 2017 in Atlanta. The followings abstracts were published today and are now available on the ASH (Free ASH Whitepaper) website at www.hematology.org (Press release, Kura Oncology, NOV 1, 2017, View Source [SID1234521438]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib in Acute Myeloid Leukemia and Myelodysplastic Syndromes (Abstract #3957)
Session Name: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster III
Date: Monday, December 11, 2017
Presentation Time: 6:00 PM – 8:00 PM
Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib: Preliminary Results from an Open-Label, Phase II Study in Relapsed or Refractory Peripheral T-Cell Lymphoma (Abstract #2788)
Session Name: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster II
Date: Sunday, December 10, 2017
Presentation Time: 6:00 PM – 8:00 PM
Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2

Preliminary Results from an Open-Label, Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia (CMML) (Abstract #2963)
Session Name: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II
Date: Sunday, December 10, 2017
Presentation Time: 6:00 PM – 8:00 PM
Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2

Killer Immunoglobulin-like Receptors (KIR) in Low-Risk Myelodysplastic Syndrome: Genotyping and Gene Expression Evaluation (Abstract #1677)
Session Name: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster I
Date: Saturday, December 9, 2017
Presentation Time: 5:30 PM – 7:30 PM
Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2

Karyopharm to Present Phase 1b/2 STOMP Clinical Data at the American Society of Hematology 2017 Annual Meeting

On November 1, 2017 Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, reported that 14 abstracts have been selected for presentation, including three oral presentations, at the upcoming American Society of Hematology (ASH) (Free ASH Whitepaper) 2017 annual meeting being held December 9-12, 2017 in Atlanta (Press release, Karyopharm, NOV 1, 2017, View Source [SID1234521436]). Four key abstracts being presented at the meeting will feature clinical data from Karyopharm’s ongoing Phase 1b/2 STOMP study evaluating selinexor, the Company’s lead, novel, oral SINE compound, in combination with backbone therapies for the treatment of patients with heavily pretreated multiple myeloma (MM). The four STOMP presentations will include updated data from the arms evaluating selinexor in combination with Velcade (bortezomib) and low-dose dexamethasone (SVd), selinexor in combination with Pomalyst (pomalidomide) and low-dose dexamethasone (SPd), and selinexor in combination with Revlimid (lenalidomide) and low-dose dexamethasone (SRd), and preliminary data from the arm evaluating selinexor in combination with Darzalex (daratumumab) and low-dose dexamethasone (SDd).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

“Despite several treatment advances for myeloma patients, there is a need for treatments with novel mechanisms, and many patients favor orally administered medicines,” said Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm. “Previously reported data from the ongoing Phase 1b/2 STOMP study showed promising response rates in patients with heavily pretreated myeloma when oral selinexor is combined with Velcade (“SVd”) or Pomalyst (“SPd”). We are very pleased to provide updated data for selinexor in combination with these agents, new data for selinexor in combination with Revlimid (“SRd”), and early results from the new Darzalex (“SDd”) combination arm at ASH (Free ASH Whitepaper) this year. We believe these data support the potential of selinexor as a backbone therapy with commonly used agents for multiple myeloma. Moreover, we believe the new data continue to support our ongoing Phase 3 BOSTON study of SVd in myeloma.”

Details for the ASH (Free ASH Whitepaper) 2017 presentations are as follows:

Phase 1b/2 STOMP Study Data Presentations

Title: Selinexor in combination with weekly low dose bortezomib and dexamethasone (SVd) induces a high response rate with durable responses in patients with refractory multiple myeloma (MM)

Presenter: Nizar Bahlis, Southern Alberta Cancer Research Institute, Calgary, Alberta

Abstract Number/Publication ID: 3135

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II

Date and Time:Sunday, December 10, 2017; 6:00-8:00 PM ET

Location: Georgia World Congress Center, Building A, Level 1, Hall A2

Title: Selinexor in Combination with Pomalidomide and Low Dose Dexamethasone in a Relapsed / Refractory Multiple Myeloma Patient Population with Prior Proteasome Inhibitor and Lenalidomide Exposure

Presenter:Christine Chen, Princess Margaret Cancer Center, Toronto, Ontario

Abstract Number/Publication ID: 3136

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II

Date and Time:Sunday, December 10, 2017; 6:00-8:00 PM ET

Location: Georgia World Congress Center, Building A, Level 1, Hall A2

Title: A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

Presenter:Darrell White, Dalhousie University and QEII Health Sciences Center, Halifax; Nova Scotia

Abstract Number/Publication ID: 1861

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Date and Time:Saturday, December 9, 2017; 5:30-7:30 PM ET

Location: Georgia World Congress Center, Building A, Level 1, Hall A2

Title: A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma Previously Exposed to Proteasome Inhibitors (PI) and Immunomodulatory Drugs (IMiDs)

Presenter:Cristina Gasparetto, Duke University Cancer Center, Durham, North Carolina

Abstract Number/Publication ID: 3100

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II

Date and Time:Sunday, December 10, 2017; 6:00-8:00 PM ET

Location: Georgia World Congress Center, Building A, Level 1, Hall A2

Investigator-sponsored Study Oral Presentations

Title: Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML

Presenter:Geoffrey Uy, Washington University School of Medicine in St. Louis

Abstract Number/Publication ID: 816

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Targeted and Immune-based Approaches in the Treatment of AML; Monday, December 11, 2017 from 4:30-6:00 PM ET

Date and Time:Monday, December 11, 2017 at 5:45 PM ET

Location: Georgia World Congress Center, Building B, Level 5, Murphy BR 1-2

Investigator-sponsored Study Poster Presentations

Title: Selinexor maintenance is feasible and tolerable after allogeneic stem cell transplant (allo-SCT) for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)

Presenter:Hongtao Liu, University of Chicago Medical Center

Abstract Number/Publication ID: 3312

Session: 732. Clinical Allogeneic Transplantation: Results: Poster II

Date and Time:Sunday, December 10, 2017 from 6:00-8:00 PM ET

Location: Georgia World Congress Center, Building A, Level 1, Hall A2

Title: A Phase I/II study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 mutated Acute Myeloid Leukemia (AML)

Presenter: Naval Daver, University of Texas MD Anderson Cancer Center

Abstract Number/Publication ID: 1344

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I

Date and Time:Saturday, December 9, 2017 from 5:30-7:30 PM ET

Location: Georgia World Congress Center, Building A, Level 1, Hall A2

Title: Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)

Presenter:Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute

Abstract Number/Publication ID: 3095

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II

Date and Time:Sunday, December 10, 2017 from 6:00-8:00 PM ET

Location: Georgia World Congress Center, Building A, Level 1, Hall A2

Preclinical Oral Presentations

Title: Non-cytotoxic Low Doses of Selinexor Promote the Differentiation of AML Cells Harboring Mutant-NPM1 into Monocytes

Presenter: Saunthararajah Yogen, Cleveland Clinic

Abstract Number/Publication ID: 105742

Session: 603. Oncogenes and Tumor Suppressors: Nuclear Export and Metabolic Regulation; Monday, December 11, 2017, 6:15-7:45 PM ET

Date and Time:Monday, December 11, 2017 at 6:30 PM ET

Location: Georgia World Congress Center, Building C, Level 1, C101 Auditorium

Title: PAK4 Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenstrom Macroglobulinemia

Presenter:Li Na, Dana Farber Cancer Institute

Abstract Number/Publication ID: 102879

Session: 622. Lymphoma Biology—Non-Genetic Studies: Novel Mechanisms Implicated in Lymphoma Biology; Monday, December 11, 2017, 10:30AM – 12:00 PM ET

Date and Time:Monday, December 11, 2017 at 11:45 AM ET

Location: Georgia World Congress Center, Building C, Level 1, C101 Auditorium

Preclinical Poster Presentations

Title: XPO1 Inhibitor Selinexor Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma (MCL) via Nuclear Retention of IκB

Presenter:Mei Ming, University of Chicago

Abstract Number/Publication ID: 104320

Session: 605. Molecular Pharmacology, Drug Resistance-Lymphoid and Other Diseases

Date and Time:Monday, December 11, 2017; 6:00-8:00 PM ET

Location: Georgia World Congress Center, Building A, Level 1, Hall A2

Title: XPO1 Inhibition Synergizes with BCR Inhibition, Blocks Tumor Growth and Prolongs Survival in a Bioluminescent Animal Model of Primary Central Nervous System Lymphoma

Presenter:Marta Crespo, Hall d’Hebron, Barcelona

Abstract Number/Publication ID: 107008

Session: 625. Lymphoma: Pre-Clinical-Chemotherapy and Biologic Agents

Date and Time:Sunday, December 10, 2017; 6:00-8:00 PM ET

Location: Georgia World Congress Center, Building A, Level 1, Hall A2

Title: Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Refractory Multiple Myeloma

Presenter:Robert Frank Cornell, Vanderbilt University Medical Center

Abstract Number/Publication ID: 107422

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II

Date and Time:Sunday, December 10, 2017; 6:00-8:00 PM ET

Location: Georgia World Congress Center, Building A, Level 1, Hall A2

About Selinexor

Selinexor (KPT-330) is a first-in-class, oral Selective Inhibitor of Nuclear Export / SINE compound. Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus. This reinitiates and amplifies their tumor suppressor function and is believed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. To date, over 2,200 patients have been treated with selinexor, and it is currently being evaluated in several mid- and later-phase clinical trials across multiple cancer indications, including in multiple myeloma in a pivotal, randomized Phase 3 study in combination with Velcade (bortezomib) and low-dose dexamethasone (BOSTON), in combination with low-dose dexamethasone (STORM) and backbone therapies (STOMP), and in diffuse large B-cell lymphoma (SADAL), and liposarcoma (SEAL), among others. Additional Phase 1, Phase 2 and Phase 3 studies are ongoing or currently planned, including multiple studies in combination with one or more approved therapies in a variety of tumor types to further inform Karyopharm’s clinical development priorities for selinexor. Additional clinical trial information for selinexor is available at www.clinicaltrials.gov.

Ironwood Pharmaceuticals to Present at Credit Suisse 26th Annual Healthcare Conference

On November 1, 2017 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) reported that it will present a corporate update at the Credit Suisse 26th Annual Healthcare Conference on Wednesday, November 8th, 2017 at 10:25 a.m. Mountain Time/ 12:25 p.m. Eastern Time at The Phoenician in Scottsdale, Arizona (Press release, Ironwood Pharmaceuticals, NOV 1, 2017, View Source [SID1234521434]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of Ironwood’s presentation will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference.